BioSyent Inc. RX
TSXV · Canada · Health Technology
CAD 16.50-0.20 (-1.20%)
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
MISSISSAUGA, Ontario, Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named as one of Canada’s Top Growing Companies for 2026 by The Globe and Mail’s Report on Business magazine. BioSyent ranked 343 on the list based on its three-year revenue growth of 54% (2022 – 2025) and is listed in the ‘Consumer’ category. “We are very proud to have been recognized as one of Canada’s Top Growing Companies,” said René Goehr
MISSISSAUGA, Ontario, Aug. 20, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its consolidated financial results for the three months (Q2), six months (H1), and trailing twelve months (TTM) ended June 30, 2026. Key highlights include: (CAD)Q2 2026 % Changevs. Q2 2025 H1 2026 % Changevs. H1 2025 TTMJun 30, 2026 % Changevs. TTMJun 30, 2025 Pharmaceutical Sales11,110,365 +14% 21,913,472 +7% 42,325,508 +11% Oral Health Sales8,224,402 n/a 11,209,375 n/a 11,209,375
MISSISSAUGA, Ontario, Aug. 20, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on September 15, 2026, to shareholders of record at the close of business on August 31, 2026. This third quarter 2026 dividend compares to a second quarter dividend of $0.055 per common share. This dividend qualifies as an 'eligible dividend' f
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.